Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
Company Overview
Si-Bone Inc. is a specialized medical device company with a focused mission to improve patient outcomes in the realm of orthopedic surgery, particularly in the treatment of sacroiliac joint dysfunction. As a pioneer in the field, Si-Bone has developed a proprietary, minimally invasive implant system aimed at facilitating sacroiliac joint fusion. Leveraging patents for titanium implant technologies, the company has made significant strides in reducing the invasiveness of traditional sacroiliac joint fusion procedures.
Core Business and Innovation
At the heart of its operations, Si-Bone’s innovative approach is encapsulated in its iFuse Implant System, which is designed to provide a reliable alternative to conventional surgical techniques. The company has successfully combined advanced engineering with practical surgical approaches to produce a system that addresses complex conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, and pelvic trauma. The product portfolio includes instruments and implantable bone products that facilitate the fusion process during minimally invasive procedures, creating a distinct market niche with several industry-specific keywords such as minimally invasive surgery, orthopedic implants, and joint fusion.
Technological Advancements
Si-Bone separates itself from competitors through its commitment to technological innovation. The iFuse Implant System, along with its variations such as iFuse-TORQ and iFuse Bedrock Granite, incorporates breakthrough design and engineering principles to ensure safety and efficacy within complex anatomical regions. These devices are supported by rigorous clinical research and designed to provide enhanced pelvic fixation, particularly during concurrent lumbar spinal fusion procedures. This focus on precision technology underscores the company’s strategic positioning within the medical device market.
Clinical and Surgical Impact
The clinical implications of Si-Bone’s technology are noteworthy, especially for patients who have traditionally faced limited treatment options in the context of sacroiliac joint dysfunction. The minimally invasive nature of the iFuse Implant System offers advantages such as reduced recovery times, fewer complications compared to traditional open surgery, and a more targeted approach in addressing structural conditions. By improving the procedural experience for both patients and surgeons, Si-Bone plays a critical role in evolving standards of care in orthopedic surgery.
Market Position and Competitive Landscape
Si-Bone operates within a highly specialized sector of the medical device industry, marked by its focus on orthopedic applications. The company’s targeted approach to sacroiliac fusion procedures and its suite of patented implant products have carved a niche in an industry characterized by continuous innovation and rigorous safety standards. While there are other players in the broader field of orthopedic devices, Si-Bone differentiates itself by addressing the challenges associated with under-diagnosed and under-treated sacroiliac joint conditions using less invasive methods. The company’s seasoned management team, with experience from major industry names, further reinforces its authority and capability in driving orthopedic innovation.
Operational Excellence and Quality Assurance
Operating under stringent regulatory frameworks, Si-Bone emphasizes both the safety and effectiveness of its implant systems. The company’s operational strategy combines deep clinical expertise with advanced technological design, ensuring each product meets high standards of quality and efficacy. By integrating comprehensive research and development with real-world surgical feedback, Si-Bone is able to continuously refine its products, aiming to maintain robust patient safety profiles and reliable clinical outcomes.
Expertise and Industry Recognition
Si-Bone’s standing in the orthopedic device community is bolstered by its innovative approaches and the robust clinical data supporting its technologies. The company’s adoption of breakthrough design methods and its ability to translate complex medical needs into effective surgical solutions showcase its technical expertise. For healthcare professionals, patients, and stakeholders, Si-Bone represents a blend of advanced engineering, clinical precision, and a commitment to minimally invasive treatment paradigms, making it a respected name within its competitive landscape.
Comprehensive Product Portfolio
The diverse portfolio from Si-Bone is characterized by a range of implant systems designed to address various orthopedic conditions. It includes systems that directly target sacroiliac joint fusion as well as those that serve broader applications such as adjacent spinal conditions and pelvic trauma. This diversified approach allows clinicians to select devices tailored to the specific needs of their patients while maintaining consistency in surgical outcomes.
Conclusion
In summary, Si-Bone Inc. is an innovator in the orthopedic medical device space, focused on developing minimally invasive, patented implant systems for sacroiliac joint fusion and related applications. Through its continuous commitment to research, quality assurance, and operational precision, the company has established a strong market presence and a clear value proposition within a niche yet critically important segment of orthopedics. Its pioneering technologies, underscored by substantial clinical validation and a robust product portfolio, position it as an informative case study for anyone seeking a deep understanding of advanced orthopedic solutions.
SI-BONE (SIBN) reported strong Q4 2024 financial results with worldwide revenue reaching $49.0 million, up 26% year-over-year. U.S. revenue grew 28% to $46.9 million. The company achieved positive adjusted EBITDA of $1.9 million in Q4, a 139% improvement.
For full-year 2024, worldwide revenue increased 20% to $167.2 million, with U.S. revenue up 21% to $158.4 million. The company reduced its net loss by 29% to $30.9 million. Gross margin remained stable at 79%.
Looking ahead, SI-BONE provided 2025 guidance, projecting worldwide revenue between $193.5-$195.5 million, representing 16-17% growth. The company expects to achieve positive adjusted EBITDA for both second half and full year 2025, with gross margins forecasted at 77-78%.
SI-BONE (SIBN) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Investors can participate in the conference call by registering through the provided link. The webcast will be available on the company's investor relations website and will remain accessible for replay for at least 90 days following the event.
SI-BONE (SIBN) has released preliminary Q4 2024 financial results, showing strong growth across key metrics. The company reported Q4 worldwide revenue between $48.8-$49.0 million, representing approximately 26% growth year-over-year. U.S. revenue reached $46.7-$46.9 million, up about 28%.
For the full year 2024, worldwide revenue was between $167.0-$167.1 million, showing 20% growth, while U.S. revenue reached $158.2-$158.4 million, up 21%. The company expanded its U.S. active physician base to approximately 1,390, representing 23% growth. SI-BONE ended Q4 with approximately $150 million in cash and marketable securities, with net cash use of about $0.8 million in the quarter. Notably, the company achieved adjusted EBITDA profitability in Q4 2024.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Piper Sandler Healthcare Conference in New York. The company's management will conduct a fireside chat on December 4, 2024, at 11:00 a.m. ET / 8:00 a.m. PT.
Investors can access the conference call through a registration link, and the live audio webcast will be available on the company's website's 'Investors' section. The webcast recording will remain accessible for replay for at least 90 days following the event.
SI-BONE reported Q3 2024 financial results with worldwide revenue of $40.3 million, up 19% year-over-year. U.S. revenue grew 18% to $38.3 million, with gross margin at 79%. The company reduced its net loss by 34% to $6.6 million and improved Adjusted EBITDA loss by 94% to $0.2 million. Notable achievements include reaching over 1,200 U.S. active physicians (15% increase) and commercializing iFuse TORQ TNT. The company updated its 2024 worldwide revenue guidance to $165-166 million and expects to achieve positive Adjusted EBITDA in Q4 2024.
SI-BONE (Nasdaq: SIBN) has received Transitional Pass-Through (TPT) payment status from CMS for its iFuse Bedrock Granite™ system, effective January 1, 2025, for up to three years. This innovative technology, used for pelvic fixation and sacroiliac joint fusion during lumbar spinal fusion procedures, will receive additional payment support without device offset in outpatient settings. The Granite system, which received FDA clearance in May 2022 and Breakthrough Device Designation in November 2021, addresses a market of approximately 130,000 annual lumbar spinal fusion procedures ending at the pelvis in the United States.
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced that it will release its third quarter 2024 financial results after the market closes on Tuesday, November 12, 2024. Following the release, the company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results.
Investors interested in participating in the conference call can register using the provided link. Additionally, a live audio webcast will be available on the 'Investors' section of SI-BONE's website. The webcast will be archived and accessible for replay for at least 90 days after the event.
SI-BONE, a medical device company focused on sacropelvic disorders, announced the first-in-patient procedures with their FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). This innovative system, which received 510(k) clearance in August 2024, addresses the challenges of pelvic fragility fractures in patients with poor bone quality. The TNT implant features a pelvis-specific design for improved fixation and reduced screw backout risk, and it is the first 3D-printed transiliac-transsacral screw cleared for market use in the U.S. Surgeons praised its streamlined instrumentation and efficient implantation process, which minimizes operating time and enhances patient recovery. SI-BONE’s CEO, Laura Francis, highlighted the system's potential to meet the unmet clinical needs of complex pelvic fractures and expand their leadership in the sacropelvic space.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will host a fireside chat on September 4, 2024, at 10:45 a.m. Eastern Time.
Investors can listen to the conference call by registering through a provided link. The webcast will be available live on the 'Investors' section of SI-BONE's website and will be archived for at least 90 days after the event. This presentation offers an opportunity for investors to gain insights into SI-BONE's operations and future prospects in the medical device industry.
SI-BONE, Inc. (Nasdaq: SIBN) has received FDA 510(k) clearance and Breakthrough Device Designation for its iFuse TORQ TNT™ Implant System (TNT). This next-generation technology is designed for pelvic fragility fracture fixation and sacroiliac joint fusion. The TNT system features a porous threaded implant capable of spanning the posterior pelvis, addressing the specific needs of the sacrum and ilium.
The FDA recognized TNT's potential to provide more effective treatment than the current standard of care, cannulated screws. TNT aims to improve early fixation and reduce screw backout, potentially allowing for earlier patient weight-bearing and mobilization. This innovation is particularly significant for the growing elderly population affected by pelvic fragility fractures.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
What is the primary focus of Si-Bone?
How does the iFuse Implant System benefit patients?
What types of conditions does Si-Bone target with its products?
How does Si-Bone differentiate itself in the orthopedic device industry?
What are the key benefits of minimally invasive surgical systems?
How does Si-Bone ensure the quality and safety of its products?
